Bioluminescence Ventures

GEMMABio is a therapeutics company dedicated to developing gene therapies for individuals with rare diseases. Its mission is to accelerate research and enhance global access to these life-changing treatments, aiming to bring gene therapy discoveries from the lab to patients worldwide more swiftly and affordably.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Nido Biosciences is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing precision medicines and small-molecule therapeutics for severe neurological and neuromuscular diseases. It employs a functional genomics platform using human cell lines and tailored screens to identify therapeutic targets driven by human genetics, with the aim of addressing the underlying biology of disease and restoring healthy cell function through targeted interventions.